GLP-1 drugs for back pain and knee OA

A narrative review published on 10 August 2026 in Current Pain and Headache Reports asks a practical question for clinicians: should GLP-1 receptor agonists have a formal place in pain medicine practice, specifically for patients with obesity-driven low back pain and knee osteoarthritis^[1]? The authors, writing from institutions including UT Health Houston, Baylor College of Medicine, and Johns Hopkins School of Medicine, say the evidence is not yet definitive, but the clinical argument for considering these drugs is strong enough that pain physicians need a framework for them.

Why obesity lands on pain specialists

The review opens with a framing that any musculoskeletal clinician will recognise: obesity is highly prevalent among patients with chronic musculoskeletal pain and is associated with low back pain, knee osteoarthritis, reduced mobility, and poorer functional outcomes^[1]. The mechanical argument is straightforward. Excess body weight raises the compressive load on every weight-bearing joint, accelerates cartilage breakdown in the knee, and correlates with higher pain scores and disability ratings across the low back and knee OA literature.

Pain physicians have historically referred obesity to primary care or endocrinology, but the patient population arriving in pain clinics has a high rate of concurrent obesity. The Hasoon review argues that this creates a scope question: at what point does treating the metabolic driver of a patient's pain fall within the remit of the pain specialist?

What weight loss does to pain and function

The review's most direct clinical finding is that weight reduction improves pain and function in obesity-related conditions^[1]. That is not a new observation. The question GLP-1 drugs introduce is whether a medication-driven weight loss of the magnitude these agents produce, around 10 to 20 percent of body weight in large Phase 3 trials, translates into pain-relevant functional gains for a population that has, historically, found that level of loss difficult to maintain.

A 2025 Nature Medicine systematic review and meta-analysis covering 56 clinical trials and more than 60,000 patients found that semaglutide was effective in reducing pain in knee osteoarthritis alongside its established cardiovascular and weight-loss benefits^[2]. That finding came from the STEP 5 and STEP 9 trial data. The magnitude of knee pain reduction in the OA population tracked closely with the magnitude of weight loss achieved.

A separate retrospective database study published in Regional Anesthesia and Pain Medicine in 2026 examined the rate of total knee arthroplasty (TKA) in patients on GLP-1 receptor agonists^[3]. After one year of GLP-1 RA use, the absolute risk of needing TKA at eight years fell by 2.80 percentage points (hazard ratio 0.90). After three years on a newer agent (semaglutide or tirzepatide), the reduction was 4.71 percentage points (HR 0.72). The authors noted that the direction of effect was consistent with mechanisms beyond weight loss alone, meaning direct anti-inflammatory or chondroprotective pathways may be contributing.

Anti-inflammatory mechanisms: what the literature reports

The Hasoon review identifies anti-inflammatory and chondroprotective effects as possible explanations for any benefit that exceeds what weight reduction alone would predict^[1]. GLP-1 receptors are expressed in tissues beyond the pancreas, including joint-relevant tissues, and preclinical work has pointed to reductions in pro-inflammatory cytokines with GLP-1 agonist exposure. The review is careful to describe this as literature-suggested rather than clinically established; there are no large prospective randomised trials in musculoskeletal pain populations specifically.

For the low back pain indication, the argument is more indirect. Adiposity is associated with systemic low-grade inflammation, and a proportion of axial pain with obesity in the background may partly reflect inflammatory load rather than pure mechanical compression. Whether reducing that inflammatory load through GLP-1 therapy translates into clinically meaningful back pain reduction independent of weight loss is not yet established in trial data.

Where these drugs sit in a pain treatment hierarchy

The review's clinical recommendation is explicit: GLP-1-based medications should not be viewed as primary analgesics or replacements for standard pain evaluation, rehabilitation, pharmacologic care, or interventional treatment^[1]. They are reasonable to consider as part of a full pain management plan in patients with obesity when excess weight plausibly contributes to chronic pain, impaired mobility, or reduced rehabilitation tolerance.

Pain physicians may either prescribe within appropriate indications and safety parameters or refer to obesity medicine or endocrinology specialists. The drugs are prescription-only across the major jurisdictions PeptideMethods tracks. For country-specific prescribing and access information, see the tirzepatide regulation pages and the semaglutide regulation pages.

What this does not cover

The review focuses on low back pain and knee osteoarthritis, which are the two conditions with the most direct epidemiological overlap with obesity. Nociceptive pain from non-weight-bearing joints, neuropathic pain, headache, and fibromyalgia all appear in the journal title but are not the primary subject of this paper. The authors describe those as areas where future research may clarify whether the drug class has a role.

There is also a practical gap between the trial populations and routine pain clinic populations. The large Phase 3 weight-loss trials enrolled adults with obesity or overweight plus specific comorbidities, not patients selected for musculoskeletal pain severity. How the pain-relevant outcomes in those trials map onto a pain clinic cohort requires prospective study.

The question the review leaves open

The central unanswered question is whether the musculoskeletal benefits from GLP-1 therapy are durable over time, particularly in the context of what happens when these drugs are stopped. The discontinuation data for tirzepatide from SURMOUNT-4 show substantial weight regain when the drug is withdrawn. If pain improvement tracks that closely with maintained weight loss, the long-term pain benefit depends on long-term drug continuation, which has its own clinical and access implications. The Hasoon review does not resolve this but acknowledges it as an open clinical and pharmacoeconomic question.^[1]

For readers: this review is written for pain specialist practitioners deciding whether to initiate or refer for GLP-1 therapy in their patient panel. The framing throughout is institutional and conservative. If you have chronic musculoskeletal pain and carry excess weight, the decision on whether GLP-1 therapy belongs in your care plan is one for a clinician who knows your full history, your comorbidities, and the access rules in your country.